We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pfizer Rounds Out Zyrtec Line With Chewable Tablet NDA Approval

This article was originally published in The Tan Sheet

22 Mar 2004

News

The Tan Sheet

Executive Summary

Pfizer hopes to increase pediatric use of its Rx allergy drug Zyrtec (cetirizine) with new 5 mg and 10 mg chewable tablets formulations, to be available starting in late April and moving to full distribution in early summer